APA (7th ed.) Citation

Sgherza, N., Battisti, O., Curci, P., Conticello, C., Palmieri, S., Derudas, D., . . . Musto, P. (2025). Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. <i>Pharmaceuticals</i> 2025, <i>18</i>, 595. MDPI AG.

Chicago Style (17th ed.) Citation

Sgherza, Nicola, et al. Correction: Sgherza Et Al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. <i>Pharmaceuticals</i> 2025, <i>18</i>, 595. MDPI AG, 2025.

MLA (9th ed.) Citation

Sgherza, Nicola, et al. Correction: Sgherza Et Al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. <i>Pharmaceuticals</i> 2025, <i>18</i>, 595. MDPI AG, 2025.